- A LUTA CONTINUA!
By Tim Horn
- Lessons from History for Today’s HIV Response
Maintaining and expanding the accomplishments of the past depend on a fight for their survival and growth—now more than ever
By Mark Harrington
- Just the Facts: Trump and the Devaluation of Science
Mobilizing to defend biomedical research investments and scientific integrity as essential for public health, safety, and well-being
By Kenyon Farrow and Mike Frick
- Wrangling Affordable Drug Pricing and HCV Elimination Under the New White House Administration
Trump’s early tough talk on drug pricing is now a pro-industry, anti-regulation GOP dreamscape
By Bryn Gay
- Resisting the Coming Austerity: Medicaid in the Crosshairs
Lingering Republican threats to the ACA and Medicaid do no favors for America’s working poor
By Annette Gaudino
- Breaking Down Walls in Trump’s Anti-Immigrant Rhetoric
How the Trump administration’s anti-immigrant stance threatens human rights, public health, and the lives of people living with TB
By Erica Lessem and Suraj Madoori
- The New War on Drugs
The 21st Century Cures Act and a right-wing war on regulations are direct threats to FDA evidentiary requirements for drugs, biologics, and devices
By Tim Horn and Suraj Madoori
New and Updated HCV Treatment Fact Sheets Now Online
February 2017 – New fact sheets on Epclusa, HCV Genotypes, and an updated fact sheet on Viekira XR and Technivie are now available.
TAG Expands Its End the Epidemic Campaign to Include Southern States Heavily Impacted by HIV
January 30, 2017 – New initiative is under way to strengthen community leadership and mobilization toward ambitious HIV prevention and treatment goals against the backdrop of anticipated shifts in federal support and resources for critical programs.
Research Toward a Cure
January 24, 2017 – A regularly updated listing of clinical trials and observational studies related to the research effort to cure HIV infection.
TAG Statement for the Record in Opposition to the Nomination of Tom Price for HHS Secretary
January 24, 2017 – Treatment Action Group (TAG) releases this statement in strong opposition to the nomination of Representative Tom Price (R-GA) for Secretary of Health and Human Services (HHS). We urge critical community action and implore the Senate Finance Committee to challenge his nomination to helm an agency that plays an exceedingly important and complex role in ending the HIV, tuberculosis (TB) and hepatitis C (HCV) epidemics in the United States and ultimately around the world.
Community Mobilization: An Assessment of Mechanisms and Barriers at Community-Based and AIDS Service Organizations in Nine U.S. Metropolitan Areas
January 9, 2017 – New Report Shines Spotlight on Need for More Investments in Community Leadership and Mobilization to End HIV as an Epidemic.
The Fair Pricing Coalition Releases New Report Urging Modernization of Existing Laws to Rein in Drug Pricing
December 7, 2016 – The Fair Pricing Coalition announces the release of “Tackling Drug Costs: A 100-Day Roadmap,” an analysis of existing federal statutes and regulations that should be strengthened to dramatically lower the prices of drugs and biologics in the U.S. The report, distributed to the President-elect’s transition team and Congressional leaders, provides a roadmap that can be implemented quickly on the heels of growing bipartisan support for feasible measures to control the skyrocketing costs of prescription medications.
Shortage of Injectable Estrogen a Crisis for Transgender Women
Public health experts call on FDA to better manage drug shortage process.
December 5, 2016 ―Today, The Fenway Institute of Fenway Health, Callen-Lorde Community Health Center, and Treatment Action Group (TAG) released a policy brief documenting the public health emergency created by a shortage of injectable estrogen, and calling on the U.S. Food and Drug Administration (FDA) to be more proactive in resolving the crisis.
HIV Activists Seek to Accelerate Development of Immune Enhancing Therapies for Immunologic Non-Responders
Dialogues with FDA, scientists and industry encourage consideration of orphan drug designations for therapies to help the immunologic non-responder population and exploration of novel endpoints to reduce the size of efficacy trials.
November 30, 2016 – A coalition of HIV/AIDS activists are calling for renewed attention to HIV-positive people termed immunologic non-responders (INRs), who experience suboptimal immune system reconstitution despite years of viral load suppression by antiretroviral therapy. Studies have shown that INR patients remain at increased risk of illness and death compared to HIV-positive people who have better restoration of immune function on current drug therapies. Risk factors for becoming an INR include older age and a low CD4 count at the time of treatment initiation. To date, efforts to develop immune enhancing interventions for this population have proven challenging, despite some candidates from small companies showing signs of promise.
Keep the Pressure on Congress: Stop 21st Century Cures
November 30, 2016 – This Morning: Urgent Action and Calls Still Needed to Stop the 21st Century Cures Act!
Update: Since last week, your critical action to block the 21st Century Cure Act (H.R. 6) during the ongoing lame-duck session of Congress has been working. Chuck Grassley (R-IA), Elizabeth Warren (D-MA), Bernie Sanders (D-VT), and Rosa DeLauro (D-CT) have all protested, calling for stopping the bill in its tracks, until significant changes are made. More urgent action is needed with calls to legislators this morning – the Senate will be increasingly influenced by how the House votes and perceives the bill.
Action Alert: Call Congress to Stop the 21st Century Cures Act
November 21, 2016 – Treatment Action Group (TAG) is calling-on organizational partners and individual activists in the fight against HIV/AIDS to contact key members of the House of Representatives urging them not to support a new version of the 21st Century Cures Act (H.R. 6) in the lame-duck session.
Increasing Funding for TB Research: An Advocacy Strategy Webinar
On November 16, 2016, TAG held a community webinar on advocacy for TB R&D funding. This webinar builds upon TAG's annual Report on Tuberculosis Research Funding Trends to begin discussion on next steps for TB R&D funding advocacy into 2017. Panelists discussed the importance of TB research and implications of stagnant funding, shared insights into what to expect in the TB R&D pipeline, and strategized on what we can do as a community to push for change and the necessary political will under a new US presidential administration.
2016 Symposium Stop Double Standards: From Prevention through Cure to ZERO TB (VIDEO)
November 17, 2016 – On October 27, 2016, in Liverpool, UK, Treatment Action Group, Advanced Access & Delivery, Harvard Medical School, Partners In Health, and the Stop TB Partnership sponsored a symposium in conjunction with the Union World Conference on Lung Health.
Reconsideration of support for impending 21st Century Cures Act
October 27, 2016—Dear Minority Leader Pelosi: On behalf of Treatment Action Group (TAG), I write to you strongly urging for the reconsideration of your support for the passage of the 21st Century Cures Act. Even as an impending and new version of the bill is set to be introduced by Energy and Commerce Chairman, Rep. Fred Upton – we are concerned that several provisions carried from the prior iteration of the bill (H.R. 6) may continue to undermine public health and jeopardize patient safety. These concerns include lowering standards for the FDA in determining approval for prospective drugs and devices, increasing the likelihood of antimicrobial resistance, to granting extended market exclusivity for new drugs.
2016 Report on Tuberculosis Research Funding Trends, 2005–2015: No Time To Lose
October 25, 2016 – Tuberculosis (TB) killed 1.8 million people in 2015, making it the most deadly infectious disease worldwide, but funding for research into better TB prevention, diagnosis, and treatment dropped by US$53.4 million, according to Treatment Action Group’s 2016 Report on Tuberculosis Research Funding Trends, 2005–2015: No Time to Lose. In 2015, the world spent US$620.6 million on TB research and development (R&D), the lowest level of funding since 2008. This marks the second straight year that funding for TB R&D has fallen, raising doubts over whether world leaders will fulfill recent promises to combat antimicrobial resistance (AMR) and eliminate TB by 2035.
Funding for Tuberculosis Research Falls to Lowest Level in Seven Years
Liverpool, United Kingdom, October 25, 2016—Tuberculosis (TB) killed 1.8 million people in 2015, making it the most deadly infectious disease worldwide, but funding for research into better TB prevention, diagnosis, and treatment dropped by US$53.4 million, according to a report issued today by Treatment Action Group (TAG). In 2015, the world spent US$620.6 million on TB research and development (R&D), the lowest level of funding since 2008. This marks the second straight year that funding for TB R&D has fallen, raising doubts over whether world leaders will fulfill recent promises to combat antimicrobial resistance (AMR) and eliminate TB by 2035.
Petition to BRICS countries to triple funding for TB R&D
October 17, 2016 – Tuberculosis (TB) is the world’s deadliest infectious disease, and research into new ways to prevent, diagnose, and treat TB is urgently needed. BRICS countries—Brazil, Russia, India, China, and South Africa—are home to nearly half of all the world’s new TB cases and deaths, yet only provide 4 percent of funding for R&D to prevent them. In anticipation of the 6th Meeting of the BRICS Health Ministers, please join our call for BRICS countries to triple funding for TB research and development (R&D).
Breakthrough: Catalyzing R&D to End TB
October 2016 – There is great hope for ending tuberculosis (TB)—the world’s leading infectious disease—thanks to both scientific progress and increased ambition from policymakers. But achieving this goal will require more investments in research and development (R&D). With funding trends distressingly on the decline for TB R&D, political action is critical to bend the curve up toward the development of breakthrough diagnostics, treatments, and vaccines needed to realize the promise of ending TB.
AN ACTIVIST’S GUIDE TO Tuberculosis Drugs 2016 Update
October 2016 – Tuberculosis (TB) has been curable for decades, but a rise in the number of people living with drugresistant TB (DR-TB) and TB/HIV coinfection challenges global targets of zero TB deaths, new infections, suffering, and stigma. Although TB and the people it affects have changed over the years, for the most part the drugs used against it have not. In 2012, bedaquiline, used to treat DR-TB, became the first new TB drug from a new class to be approved by the U.S. Food and Drug Administration (FDA) in over 40 years; its accelerated approval was followed in 2014 by the European Medicines Agency’s (EMA’s) conditional approval of bedaquiline and another new drug, delamanid, for the treatment of some forms of DR-TB.
- HEALTH, HUMAN RIGHTS, and SOCIAL JUSTICE
By Tim Horn
- Science and Solidarity
Using human rights to strengthen TB research and access
By Mike Frick
- Who’s Responsible?
Pharma’s Obligations Under the Right to Science
By Erica Lessem and Brian Citro
- Countering the Contagion of Racism Through Resistance
Upholding narratives of Black science and treatment activism, and community mobilization in HIV/AIDS and TB
By Suraj Madoori
- Beyond Tuskegee
A case for a racial justice agenda in treatment and research
By Kenyon Farrow
- Decriminalization is a Public Health Strategy
We can’t end the viral hepatitis epidemics unless we end the war on drug users
By Annette Gaudino
- Rallying the Multitude to Free the (generic) HCV Cure
Effective responses to the burgeoning hepatitis C pandemic requires solidarity between the global North and South
By Bryn Gay
- Toward Health Equity
We will not end HIV as an epidemic without the expertise and leadership of Black and Latino gay and bisexual men and transgender people of color.
By Jeremiah Johnson
TAG Responds to the Release of the World Health Organization's 2016 Global Tuberculosis Report
October 13, 2016 – TB is a preventable, curable disease, and the dismal lack of progress against reversing the TB epidemic is unacceptable. Last year, the World Health Organization (WHO) reported that TB had overtaken HIV as the world's leading cause of death from an infectious disease, and this year the WHO numbers show that the TB epidemic is larger than previously estimated.
September 28, 2016 – Treatment Action Group, in conjunction with the Human Rights Campaign (HRC) and the Fair Pricing Coalition Launch #FairDrugPricesNow Campaign, a new effort to organize the LGBTQ community around common-sense solutions to drug pricing and price increasing.
Epclusa Fact Sheet
September 20, 2016 – Available in English and Spanish as PDF downloads.
Letter to Hillary Clinton on HCV Drug Prices
September 19, 2016 – Dear Secretary Clinton, As a national group of healthcare providers, advocates, and patients dedicated to preventing and treating viral hepatitis, we welcome your recent comments in Cleveland regarding the high price of pharmaceutical drugs to cure the hepatitis C virus (HCV). We are encouraged by the broad support for government action on the high price of pharmaceutical drugs, especially those for viral hepatitis, and to see this issue being directly addressed by elected officials at all levels of government. However, we are writing you today out of concern that your current healthcare platform does not specifically or adequately address the national and international viral hepatitis epidemics. We must work together to raise the profile of hepatitis B and C as urgent public health priorities.
WORLD HEPATITIS DAY 2016 – Direct-Acting (Antiviral) Generics Work: Free the cure!
July 28, 2016 – To mark the significance of World Hepatitis Day, Médecins du Monde (MdM) and Treatment Action Group (TAG) have produced a new report Dying at these prices: Generic HCV cure denied, based on crowdsourced hepatitis C data from over 40 countries available at mapCrowd.org.
2016 Pipeline Report
July 15, 2016 – HIV and TB Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development
Webinar: The stigma of HIV prevention
July 13, 2016
Breathing Life into Flatlined U.S. Government Funding for Tuberculosis Research: FY 2017–2020 Allocations and Recommendations
June 2016 – This policy brief provides an overview of investments made by the U.S. government and explains how increasing TB R&D funding can catalyze the development of better vaccines, diagnostics, and treatments for TB. It is built upon resource tracking and reporting done by Treatment Action Group (TAG), and it recommends areas in which investments will not only fill research gaps but also provide clarity in the vision proposed by the National Action Plan and prevent the rising threat of multidrug-resistant TB (MDR-TB).
New and Updated HCV Treatment Fact Sheets Now Online
May 31, 2016 – A new fact sheet on Zepatier, and updated fact sheets on Solvaldi, Harvoni, Viekira Pak, and Daklinza now available for download.
An Open Letter to Senator Sanders Challenging the Characterization of Meeting with HIV/AIDS Activists
May 27, 2016 – Dear Senator Sanders: We are grateful that you took time to sit with us this week to discuss a broad range of issues related to the fight against HIV/AIDS. Our group represents a larger coalition of over 70 organizations and advocates from across the country who hope to use this opportunity to push forward the national conversation, which is sorely missing, about HIV/AIDS. While we were optimistic following what we felt was a productive meeting, our optimism quickly turned to disappointment when your campaign issued a news release misrepresenting the meeting with HIV/AIDS leadership entitled “Sanders Backs California Ballot Initiative to Rein in Drug Prices at Meeting with HIV/AIDS Advocates.”
Hepatitis C: No More Treatment Rationing; Universal Access to Generic Medicines Everywhere!
April 16, 2016, Barcelona – People with hepatitis C virus (HCV) and their allies from Spain and around the world have gathered at the International Liver Congress to protest the outrageous price of life-saving HCV medicines. They are pushing for generic competition to bring down the price of HCV treatment and ensure universal access.
TAGline Spring 2016
NEWS ON THE FIGHT TO END HIV/AIDS, VIRAL HEPATITIS, AND TUBERCULOSIS
- Fair Pricing: Reclaiming Drugs for the Common Good
By Tim Horn
- Greed and the Necessity for Regulation
The story of U.S. drug pricing run amok isn’t just about corporate arrogance and avarice—it is also about government permissiveness and inaction
By Tim Horn, Erica Lessem, and Kenyon Farrow
- PrEP Pricing Problems
A number of barriers to pre-exposure prophylaxis (PrEP) uptake, use, and adherence have been identified—cost shouldn’t be one of them
By James Krellenstein and Jeremiah Johnson
- The Low Cost of Universal Access
Generic treatments for HIV, viral hepatitis, and cancer can be affordably—and profitably—mass-produced for broad, unobstructed availability
By Tracy Swan
AIDS Advocates from Across the U.S. Call upon Presidential Candidates to Make Ending the Epidemic a Priority
March 15, 2016 – Secretary Clinton's mischaracterization of the Reagan Administration on Friday, March 11, sparked nationwide upset from HIV/AIDS advocates, service providers, people living with HIV, and loved ones of those lost to the epidemic. But it also has created an opportunity to bring HIV/AIDS to the forefront of the conversation during this campaign season.
HIV Community Letter to Hillary for America
March 14, 2016 – Dear Secretary Clinton: We write to you in the sincere hope that we can work together to transform the pain caused by your March 11th mischaracterization of the Reagans’ role in the AIDS crisis into an urgently needed public discussion of a plan to end the United States HIV epidemic by the year 2025.
TAG Welcomes Delamanid’s Inclusion in the Stop TB Partnership’s Global Drug Facility
February 24, 2016 – Treatment Action Group (TAG) congratulates the Stop TB Partnership and Otsuka Pharmaceutical for arranging for the inclusion of delamanid, an important new medicine for treating some cases of multidrug-resistant tuberculosis (MDR-TB), in the Global Drug Facility (GDF). TB is the leading infectious cause of death globally, and new medicines to treat drug-resistant strains of TB are urgently needed. TAG commends the GDF and the Stop TB Partnership for their leadership in securing access to delamanid with minimal barriers and at a single flat price for all Global Fund-eligible countries.
Pre-CROI Community HIV Cure Research Workshop 2016
February 22, 2016 – On Sunday February 21, 2016, in Boston, the AIDS Treatment Activists Coalition, AVAC, European AIDS Treatment Group, Project Inform, and TAG co-sponsored a community workshop on HIV cure research. The workshop has become an annual event that takes place immediately prior to the Conference on Retroviruses and Opportunistic Infections (CROI). Slide presentations are available at the link above, and there is coverage of workshop on the EATG at CROI 2016 Facebook page.
Treatment Action Group Hails Governor Cuomo’s Proposed Legislation Allowing Minors to Maintain Confidentiality When Obtaining HIV Treatment or Preventive Therapy
February 11, 2016 – “Governor Cuomo continues to provide globally unprecedented leadership with New York State's plan to end AIDS as an epidemic by the year 2020,” said Treatment Action Group executive director Mark Harrington. “With today's announcement that he will submit legislation allowing minors to consent to receive antiretroviral therapy (ART) or pre-exposure prophylaxis (PrEP) to treat or prevent HIV infection, New York State moves closer to achieving an AIDS-free generation in this decade. Treatment Action Group salutes the governor's sustained leadership in these efforts and calls on state legislators to rapidly and unanimously pass this lifesaving, infection-averting legislation to end AIDS and HIV acquisition among our state's youth."
MapCrowd: An Online Data Collection Platform for Hepatitis C information
February 8, 2016 – Médecins du Monde (MdM) and Treatment Action Group (TAG) are pleased to announce the launch of mapCrowd (www.mapCrowd.org), an innovative online resource and data collection platform for gathering and sharing hepatitis C information.
TAG’s Response to the U.S. Action Plan for Combating Multidrug-Resistant Tuberculosis
January 7, 2016 – Treatment Action Group (TAG) welcomes the release of the Obama Administration’s National Action Plan for Combating Multidrug-Resistant Tuberculosis. Strengthening the domestic and global and research efforts to address multidrug-resistant tuberculosis (MDR-TB) are critical to ending the suffering this preventable, curable disease needlessly causes. However, the targets set forth in this plan are not ambitious enough to effectively stop the spread of MDR-TB. The Administration and Congress must appropriate funding levels to ensure that the U.S. can effectively address MDR-TB.
HCV Fact Sheets in English and en Español
December 14, 2015 – This set of fact sheets include information on adherence to treatment, HCV diagnostics, and currently approved treatments (Sovaldi, Olysio, Viekira Pak and Technivie, Harvoni, Daklinza, and ribavirin).
TAG’S PROGRESS ON THE FIGHT TO END HIV/AIDS, VIRAL HEPATITIS, AND TUBERCULOSIS
December 13, 2015
- Letter from Kenyon Farrow, TAG's U.S. & Global Health Policy Director
- Message from Board President Barbara Hughes
- Ending the Epidemic Update
- HCV Report from the Front
The Fair Pricing Coalition (FPC) applauds the Wyden-Grassley US Senate bipartisan Sovaldi investigation spotlighting a greed-driven pricing strategy behind Gilead’s $1,000 per pill hepatitis C drug launch
December 3, 2015 – “This remarkable investigative report is an indictment against Gilead and the US drug pricing system which allows lifesaving drugs to be priced beyond what the market can reasonably bear,”
Webinar: Envisioning comprehensive HIV prevention service delivery in the US
Join Treatment Action Group and the HIV Prevention Justice Alliance for a webinar on Thursday, Dec. 17, 2 to 3:30 p.m. ET as we discuss the current state of the HIV prevention toolbox and an introduction to the HIV prevention continuum. Moderated by TAG's Jeremiah Johnson.
An Activist’s Guide to Regulatory Issues: Ensuring Fair Evaluation of and Access to Tuberculosis Treatment
December 2015 – This guide explains different regulatory processes and terms and offers examples of how to use a variety of regulatory mechanisms to improve access to treatment. The guide also encourages activists to advocate for effective, efficient, transparent regulatory systems.
Tuberculosis Research Funding Crisis Imperils Elimination Goal
November 30, 2015, Cape Town, South Africa – Worldwide funding for tuberculosis (TB) research fell $1.3 billion short of global targets in 2014, according to a report released today by Treatment Action Group (TAG). Total funding of US$674,036,492 in 2014 amounted to barely one-third of the US$2 billion experts estimate the world must spend on TB research and development (R&D) each year to eliminate TB. Alarmingly, funding for TB drug research fell by US$25 million compared with 2013. Overall, funding for TB R&D fell by US$12 million.
Symposium: Scale Up to Get Down to Zero TB Deaths, New Infections, and Suffering
In conjunction with the 2015 Union World Conference on Lung Health Conference
Friday, December 4, 2015
18h00 – 20h30
Southern Sun The Cullinan, Protea 1 & 2
1 Cullinan Street Cape Town Waterfront
Cape Town, South Africa 8001
TAG's Response to Sen. Cassidy Statements on AIDS Research Spending
November 19, 2015 – I would like to offer comments to correct the record on statements given by Senator Bill Cassidy (R-LA) at the October 7, 2015, hearing on the National Institutes of Health fiscal year 2016 budget. Several of his comments to the committee and NIH Director Francis Collins were incorrect or misleading. If his erroneous statements about AIDS research funding at the NIH are mistaken for fact, we will set a dangerous course for current and future research being conducted at the agency and undermine the prioritization process under way at the Office of AIDS Research (OAR).
TAG Response to the Release of the World Health Organization’s 2015 Global Tuberculosis Report
October 28, 2015 – Global leaders’ half-hearted response has enabled TB to overtake AIDS as the world’s leading cause of death from an infectious disease.